« Back
Home /
Cloperastine fendizoate

Cloperastine fendizoate

Item no.	HY-B2179-100mg
Manufacturer	MedChem Express
CASRN	85187-37-7
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 500 mg
Category	Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.00
Citations	[1]Takahara A, et al. Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs. J Pharmacol Sci. 2012;120(3):165-75.\|[2]Catania MA, et al. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther Clin Risk Manag. 2011;7:83-92.
Smiles	O=C(O)C1=CC=CC=C1C(C2=CC(C3=CC=CC=C3)=C(O)C=C2)=O.ClC4=CC=C(C(C5=CC=CC=C5)OCCN6CCCCC6)C=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	85187-37-7
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Potassium Channel
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	648.19
Product Description	Cloperastine fendizoate inhibits the hERG K+ currents in a concentration-dependent manner with an IC50 value of 27 nM.
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO: 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B2179-100mg-safety-datasheet.pdf